RIVAROXABAN WITH OR WITHOUT ASPIRIN IN STABLE CARDIOVASCULAR DISEASE - COMPASS TRIAL

Authors

  • Ana Beatriz Brenner Affonso da Costa Universidade Federal do Paraná - Hospital de Clínicas
  • Fernanda Perin Maia da Silva Universidade Federal do Paraná - Hospital de Clínicas
  • Mauricio de Carvalho Universidade Federal do Paraná - Hospital de Clínicas

DOI:

https://doi.org/10.5380/rmu.v4i3.56402

Abstract

In this Journal Club we discuss the COMPASS study, which evaluated the efficacy and safety of Rivaroxaban for the prevention of serious adverse cardiac events including cardiovascular death, acute myocardial infarction (IAM) and stroke in patients with coronary artery disease or peripheral artery disease. When compared to ASA alone, the combination of low-dose Rivaroxaban (2,5 mg twice daily) with 100 mg daily ASA was associated with a reduction in ischemic events and mortality, without significantly increasing the rate of severe bleeding.

References

The COMPASS Investigators. Rivaroxaban with or

without Aspirin in Stable Cardiovascular Disease. N

Engl J Med 2017; Aug 27:[Epub ahead of print]

http://www.nejm.org/doi/full/10.1056/

NEJMoa1709118

Downloads

Published

2017-11-19

How to Cite

Costa, A. B. B. A. da, Silva, F. P. M. da, & Carvalho, M. de. (2017). RIVAROXABAN WITH OR WITHOUT ASPIRIN IN STABLE CARDIOVASCULAR DISEASE - COMPASS TRIAL. Revista Médica Da UFPR, 4(3), 151–154. https://doi.org/10.5380/rmu.v4i3.56402

Issue

Vol. 4 No. 3 (2017)

Section

Journal Club

License

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).